Loading…
CRISPR Therapeutics AG is projected to rise to $57.14 by 2027, a +18% move from its current price of $48.44. CRSP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $47.29 | $48.46 | $49.67 | +0.05% |
| Aug 2 | $46.84 | $48.49 | $50.20 | +0.10% |
| Aug 3 | $46.49 | $48.51 | $50.61 | +0.14% |
| Aug 4 | $46.21 | $48.53 | $50.97 | +0.19% |
| Aug 5 | $45.97 | $48.56 | $51.29 | +0.24% |
| Aug 6 | $45.75 | $48.58 | $51.58 | +0.29% |
| Aug 7 | $45.55 | $48.60 | $51.86 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $45.55 | $48.60 | $51.86 | +0.34% |
| Week 2 | $44.49 | $48.77 | $53.45 | +0.67% |
| Week 3 | $43.73 | $48.93 | $54.74 | +1.01% |
| Week 4 | $43.12 | $49.09 | $55.89 | +1.35% |
| Week 5 | $42.61 | $49.26 | $56.94 | +1.69% |
| Week 6 | $42.17 | $49.42 | $57.93 | +2.03% |
| Week 7 | $41.77 | $49.59 | $58.87 | +2.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CRISPR Therapeutics AG is a healthcare company focused on gene editing to develop gene-based medicines using its CRISPR/Cas9 platform. It has a portfolio across disease areas including hemoglobinopathies, CAR T cell therapies, in vivo approaches, and type 1 diabetes, and develops investigational CAR T programs. The lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 cell therapy for treating transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient’s hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells.
It also develops CAR T therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address cardiovascular disease by disrupting validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of type 1 diabetes. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG (CRSP) is a healthcare company focused on gene editing. Its current price is $46.99 and its market cap is $4.63B, with a rank of 1340. The near-term price path shows a neutral stance in 2026, with a bullish long-term trajectory indicated by year-by-year averages and ROIs.
A major floor 23.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.9% below — buyers have tended to step in here.
The nearest ceiling, 27.8% above — a clean break opens room to run.
A major ceiling 39.6% above — clearing it would confirm fresh momentum.
Key CRSP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRSP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $47.38 | Buy | $47.78 | Buy |
| MA 10 | $47.46 | Buy | $48.30 | Buy |
| MA 20 | $51.36 | Sell | $49.84 | Sell |
| MA 50 | $52.20 | Sell | $51.53 | Sell |
| MA 100 | $51.75 | Sell | $52.29 | Sell |
| MA 200 | $54.14 | Sell | $52.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.97 | Neutral |
| Stoch RSI (14) | 99.98 | Sell |
| CCI (20) | -44.83 | Neutral |
| Williams %R (14) | -60.66 | Info |
| MACD (12,26,9) | -0.25 | Sell |
| ROC (12) | -4.00 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 39.34 | Neutral |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | -4.87 | Sell |
| Ultimate (7,14,28) | 45.65 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 47.70 | Buy |
| ADX (14) | 19.48 | Neutral |
| ATR (14) | 1.14 | Info |
The 30-day technical picture is bearish, with RSI14 at 40. The stock trades below the SMA50 of $52.89 and the SMA200 of $55.11, signaling softer near-term momentum. Support is at $46.99 and resistance at $61.89, marking key levels traders watch.
The 30-day price range runs from $38.67 to $57.10, highlighting a fairly wide swing in recent sessions. Annualized volatility is high at 60%, underscoring substantial move potential in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $44.34 | $48.44 | $63.78 | 0% | Neutral | |
| $45.99 | $57.14 | $74.78 | +18% | Neutral | |
| $49.61 | $63.20 | $85.60 | +30% | Bullish | |
| $62.35 | $81.08 | $112.78 | +67% | Bullish | |
| $68.16 | $90.26 | $128.40 | +86% | Bullish | |
| $66.63 | $89.70 | $130.12 | +85% | Bullish | |
| $72.45 | $99.04 | $146.23 | +104% | Bullish | |
| $74.12 | $102.78 | $154.18 | +112% | Bullish | |
| $81.15 | $114.06 | $173.64 | +135% | Bullish | |
| $99.55 | $141.74 | $218.74 | +193% | Bullish | |
| $118.76 | $179.25 | $292.94 | +270% | Bullish | |
| $230.40 | $383.97 | $682.34 | +693% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $44.34 | $48.44 | $56.46 | +0.00% |
| August 2026 | $42.30 | $49.53 | $59.28 | +2.26% |
| September 2026 | $42.88 | $50.60 | $61.29 | +2.15% |
| October 2026 | $42.06 | $49.92 | $61.05 | -1.34% |
| November 2026 | $41.90 | $49.99 | $61.60 | +0.13% |
| December 2026 | $42.89 | $51.39 | $63.78 | +2.81% |
Click any year to see its month-by-month CRSP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CRISPR Therapeutics AG's 2026 outlook centres on $48.44, within a $44.34 to $63.78 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CRSP could reach as high as $74.78, with a base case around $57.14 and support toward $45.99 — roughly +18% from $48.44. Price action looks broadly range-bound.
Expect CRSP to range from $49.61 to $85.60 through 2028. The $63.20 average target implies a +30% move from current prices. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CRSP price prediction for 2029 points to an average of $81.08 (low $62.35, high $112.78) — a potential gain of +67% on today's $48.44. Momentum favours further upside here.
In 2030, CRSP is projected to trade between $68.16 and $128.40, averaging $90.26 — a potential gain of +86% from today's $48.44. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
CRISPR Therapeutics AG's 2031 outlook centres on $89.70, within a $66.63 to $130.12 range. That is -1% versus the projected 2030 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2032, CRSP could reach as high as $146.23, with a base case around $99.04 and support toward $72.45 — roughly +104% from $48.44. Buyers look set to stay in control over this stretch.
Expect CRSP to range from $74.12 to $154.18 through 2033. The $102.78 average target implies a +112% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The CRSP price prediction for 2034 points to an average of $114.06 (low $81.15, high $173.64) — a potential gain of +135% on today's $48.44. Buyers look set to stay in control over this stretch.
In 2035, CRSP is projected to trade between $99.55 and $218.74, averaging $141.74 — a potential gain of +193% from today's $48.44. That is up +24% on the projected 2034 average. Momentum favours further upside here.
CRISPR Therapeutics AG's 2040 outlook centres on $179.25, within a $118.76 to $292.94 range. That is up +26% on the projected 2035 average. That marks a +270% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CRSP could reach as high as $682.34, with a base case around $383.97 and support toward $230.40 — roughly +693% from $48.44. Momentum favours further upside here.
Investing $1,000 in CRSP today (≈ 20.644096 CRSP) could be worth
$7,926.76
+$6,926.76 (+693%) by 2050 · US Dollar
Based on the average projected CRSP price of $383.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRSPwould be worth at today's price.
$1,000 invested in CRSP on Jul 30, 2025 (≈ 17.337032 CRSP) would be worth
$839.81
-$160.19 (-16.0%) today · 0.84× · US Dollar
Based on a CRSP entry price of $57.68 vs. today's $48.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $47.53 | $1,019.15 | +1.9% |
| 1 month ago | $54.54 | $888.16 | -11.2% |
| 3 months ago | $51.63 | $938.21 | -6.2% |
| 6 months ago | $49.96 | $969.58 | -3.0% |
| 1 year ago | $57.68 | $839.81 | -16.0% |
| All time (5.0y) ago | $122.34 | $395.95 | -60.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRSP forecast.
Our base-case forecast reaches $97.00 around 2032.
Implied market cap at $97.00: $9.55B
The multi-year forecast shows a bullish trend after a neutral start in 2026, with the average price rising across successive years. Notable anchors include 2026 avg $46.99, 2027 avg $52.23 (ROI 11.1%), 2028 avg $56.92 (ROI 21.1%), 2029 avg $73.85 (ROI 57.2%), and 2030 avg $80.37 (ROI 71%). The forecast remains bullish through 2031–2035 (e.g., 2031 avg $77.91, ROI 65.8%; 2032 avg $84.78, ROI 80.4%; 2033 avg $84.88, ROI 80.6%; 2034 avg $93.08, ROI 98.1%; 2035 avg $117.25, ROI 149.5%).
Looking further ahead, 2040 is expected to yield an avg of $139.43 (ROI 196.7%) and 2050 an avg of $294.37 (ROI 526.4%). The forecast carries a bullish sentiment for the long horizon. These are estimates, not guarantees, and depend on market conditions and execution risk.
Tap a question to reveal the answer.
2030 forecast: avg $80.37, min $58.75, max $118.77, ROI 71%, sentiment BULLISH.
Near term (2026) shows avg $46.99 with ROI 0% and sentiment NEUTRAL, transitioning to bullish in later years (e.g., 2027 avg $52.23, ROI 11.1%; 2028 avg $56.92, ROI 21.1%). The longer-term outlook remains bullish with rising averages and ROIs.
Technical resistance is $61.89. The 30-day range high is $57.10, and the forecast for 2026 shows a max of $62.35, suggesting potential to test or surpass resistance if conditions allow.
2040 forecast: avg $139.43, max $241.60, min $86.37, ROI 196.7%, sentiment BULLISH.
2050 forecast: avg $294.37, max $560.77, min $160.15, ROI 526.4%, sentiment BULLISH.
CRISPR Therapeutics AG Community Discussion
0Share your CRISPR Therapeutics AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.